Assembly Biosciences Valuation Multiples

Assembly Biosciences Overview

About Assembly Biosciences

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Founded

2005

HQ

Employees

73

Website

assemblybio.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $68M

EBITDA: ($2M)

EV

$228M

Valuation Multiples

Multiples.vc

Start free trial

Assembly Biosciences Financials

Assembly Biosciences reported last 12-month revenue of $68M and negative EBITDA of ($2M).

In the same LTM period, Assembly Biosciences generated $68M in gross profit, ($2M) in EBITDA losses, and had net loss of ($15M).

Assembly Biosciences P&L

In the most recent fiscal year, Assembly Biosciences reported revenue of $72M and EBITDA of ($12M).

Assembly Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX

Assembly Biosciences Stock Performance

Assembly Biosciences has current market cap of $474M, and enterprise value of $228M.

Assembly Biosciences' stock price is $29.85.

Assembly Biosciences Valuation Multiples

Assembly Biosciences trades at 3.4x EV/Revenue multiple, and (95.7x) EV/EBITDA.

Assembly Biosciences Financial Valuation Multiples

As of April 11, 2026, Assembly Biosciences has market cap of $474M and EV of $228M.

Equity research analysts estimate Assembly Biosciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Assembly Biosciences has a P/E ratio of (32.5x).

Assembly Biosciences Margins & Growth Rates

Assembly Biosciences' revenue in the last 12 month declined by (17%).

Assembly Biosciences' revenue per employee in the last FY averaged $1.0M, while opex per employee averaged $1.2M for the same period.

Assembly Biosciences' rule of 40 is 19% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Assembly Biosciences' rule of X is (16%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Assembly Biosciences Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Assembly Biosciences M&A Activity

Assembly Biosciences acquired XXX companies to date.

Last acquisition by Assembly Biosciences was on XXXXXXXX, XXXXX. Assembly Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Assembly Biosciences Investment Activity

Assembly Biosciences invested in XXX companies to date.

Assembly Biosciences made its latest investment on XXXXXXXX, XXXXX. Assembly Biosciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).